The Analyst Landscape: 4 Takes On Amicus Therapeutics
Portfolio Pulse from Benzinga Insights
Amicus Therapeutics (NASDAQ:FOLD) received mixed analyst ratings in the last quarter, with 2 somewhat bullish and 2 indifferent ratings. The average 12-month price target for FOLD is $17.00, with a high of $20.00 and a low of $14.00. This target has increased by 11.48% over the past month. Analysts from Morgan Stanley and JP Morgan have adjusted their price targets and ratings, reflecting their latest views on the company's performance and market conditions. Amicus Therapeutics is a biotech company focused on rare metabolic diseases, showing strong revenue growth and efficient cost management but facing challenges in debt management.
December 19, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amicus Therapeutics received mixed ratings, with an average price target of $17.00, reflecting a positive sentiment from analysts. The company's strong revenue growth and efficient cost management are positive indicators, while high debt levels pose a risk.
The average price target increase and the mixed but somewhat bullish ratings suggest a cautiously optimistic outlook for FOLD. The company's revenue growth and net margin are positive, but the high debt-to-equity ratio could be a concern for short-term investors. The confidence score reflects the recent positive changes in analyst ratings and price targets, which typically influence investor sentiment and can lead to short-term price increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100